SEC Company Response from CNBX Pharmaceuticals (CNBX) — Apr 19, 2017

CNBX Pharmaceuticals Inc.
Date: April 19, 2017 · CIK: 0001343009 · Accession: 0001683168-17-000976

View on Edgar

AI Filing Summary & Sentiment

File numbers found in text: 333-216845

Date

April 19, 2017

Author

/s/ Itamar Borochov

Form

CORRESP

Company

CNBX Pharmaceuticals Inc.

Letter

VIA EDGAR Division of Corporation Finance Office of Healthcare and Insurance Securities and Exchange Commission Re: Cannabics Pharmaceuticals, Inc. Registration Statement on Form S-3 – Request for Acceleration Originally Filed March 21, 2017 File No. 333-216845

Dear Sirs:

Thank you for advising us that the Commission has reviewed the above-referenced registration statement (the “Registration Statement”) of Cannabics Pharmaceuticals, Inc. (the “Company”). The Company hereby requests acceleration of the effective date of the Registration Statement to April 21, 2015 at 1:00 p.m. or as soon thereafter as practicable, and as part of this request acknowledges the following:

· should the Commission or the staff, acting pursuant to delegated authority, declare the Registration Statement effective pursuant to this request, it does not foreclose the Commission from taking any action with respect to the Registration Statement;

· the action of the Commission or the staff, acting pursuant to delegated authority, in declaring the Registration Statement effective, does not relieve the Company from its full responsibility for the adequacy and accuracy of the disclosure in the Registration Statement; and

· the Company may not assert staff comments and the declaration of effectiveness as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States.

If you need any additional information for purposes of this request, please contact me at +972-54-948-7653.

Sincerely,
/s/ Itamar Borochov

Show Raw Text

CORRESP
1
filename1.htm

Cannabics Pharmaceuticals, Inc.

#3 Bethesda Metro Center

Suite 700

Bethesda, MD 20814

April 19, 2017

VIA EDGAR

Division of Corporation Finance

Office of Healthcare and Insurance

Securities and Exchange Commission

Washington DC 20549

Re:  Cannabics Pharmaceuticals, Inc.

Registration Statement on Form S-3 – Request
for Acceleration

 Originally Filed March 21, 2017

File No. 333-216845

Dear Sirs:

Thank you for advising us that the Commission
has reviewed the above-referenced registration statement (the “Registration Statement”) of Cannabics Pharmaceuticals,
Inc. (the “Company”). The Company hereby requests acceleration of the effective date of the Registration Statement
to April 21, 2015 at 1:00 p.m. or as soon thereafter as practicable, and as part of this request acknowledges the following:

 · should the Commission or the staff, acting pursuant to delegated authority, declare the Registration
Statement effective pursuant to this request, it does not foreclose the Commission from taking any action with respect to the Registration
Statement;

 · the action of the Commission or the staff, acting pursuant to delegated authority, in declaring
the Registration Statement effective, does not relieve the Company from its full responsibility for the adequacy and accuracy of
the disclosure in the Registration Statement; and

 · the Company may not assert staff comments and the declaration of effectiveness as a defense in
any proceeding initiated by the Commission or any person under the federal securities laws of the United States.

If you need any additional information for
purposes of this request, please contact me at +972-54-948-7653.

     Sincerely,

/s/ Itamar Borochov

Itamar Borochov

Chief Executive Officer

Cannabics Pharmaceuticals, Inc.

SecProbe.io